Home › Trials › NCT06896916

IV etentamig plus oral iberdomide for adults with relapsed or refractory multiple myeloma

Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Phase 1 Interventional AbbVie · NCT06896916

This trial will test whether IV etentamig given with oral iberdomide is safe and changes disease activity in adults with relapsed or refractory multiple myeloma.

Quick facts

PhasePhase 1
Study typeInterventional
Enrollment135 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsCAR-T, chimeric antigen receptor
Locations27 sites (Beverly Hills, California and 26 other locations)
Trial IDNCT06896916 on ClinicalTrials.gov

What this trial studies

This Phase 1, dose‑escalation study gives adults with relapsed or refractory multiple myeloma escalating IV doses of etentamig together with oral iberdomide across multiple treatment arms to identify tolerable dosing and record adverse events. About 135 participants are expected to enroll at roughly 50 sites worldwide, with safety and change in disease activity as the primary focuses. Participants receive different dose combinations and are monitored regularly with central laboratory measurements to track measurable disease and side effects. The protocol allows certain prior BCMA-directed therapies (such as CAR‑T or ADC) under specified conditions.

Who should consider this trial

Good fit: Adults with measurable relapsed or refractory multiple myeloma, ECOG performance status 0–1, who have not previously received etentamig or prior CELMoD agents and can attend scheduled visits are ideal candidates.

Not a fit: Patients who previously received etentamig or prior CELMoD agents (iberdomide or mezigdomide), those with poor performance status, or those with contraindications to the study drugs are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, this combination could provide a new treatment option that reduces tumor burden or delays progression for some patients with relapsed or refractory multiple myeloma.

How similar studies have performed: Other CELMoD agents such as iberdomide have shown activity in relapsed multiple myeloma and combinations with novel agents are promising, but etentamig itself is investigational with limited prior clinical data.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1.
* Must have confirmed diagnosis of Relapsed/Refractory Multiple Myeloma (RRMM) after the participant's last treatment, as outlined in the protocol.
* All participants must have measurable diseases per central laboratory as outlined in protocol

Exclusion Criteria:

* Has received prior etentamig treatment.
* Prior exposure to BCMA-targeted therapy as noted in the protocol.
* Has received prior cereblon E3 ligase modulatory drug (CELMoD) (iberdomide or mezigdomide).

Where this trial is running

Beverly Hills, California and 26 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Multiple MyelomaCereblon E3 Ligase Modulatory DrugCELMoDIberdomideEtentamigABBV-383
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.